06 Dec Eylea As Good As Lucentis
The FDA approved Eylea as a new treatment for wet macular degeneration. Recent reports indicate the drug is similar to Lucentis after the initial year of treatment. Why is this bad news?...
The FDA approved Eylea as a new treatment for wet macular degeneration. Recent reports indicate the drug is similar to Lucentis after the initial year of treatment. Why is this bad news?...
Alimera Sciences suffers set back with Iluvien. In a complete response letter to the company, the FDA did not approve the device for diabetic retinopathy citing concerns over safety....
The American Academy of Ophthalmology starts this week. I will be going to learn about the latest in retinal disease, but also will be teaching...
VEGF Trap Eye is another anti-VEGF medication to be injected into the eye for the treatment of wet macular degeneration. The FDA did not approve recently, but will reconsider by November!...
A new study finds the combination of laser treatment with intraocular injections of anti-VEGF to be the best treatment for diabetic retinopathy....
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received "priority review" status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10 month period....
VEGF Trap-Eye is a new injectable medication that blocks VEGF for the treatment of wet macular degeneration. It may be as good as Lucentis, but not given as often....
anti-VEGF medications are standard for the treatment of macular degeneration, but may also become very effective treatments for diabetic eye disease....
Diabetic retinopathy causes the retina to lose blood supply. A chain events causes liberation of VEGF and can lead to blindness....
A new study finds that by combining Lucentis with laser treatment for diabetic retinopathy results in excellent visual outcomes....